pp-061 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Type 2 diabetes mellitus with concurrent hypertension requiring combination oral therapy to improve glycemic control and blood-pressure management.
Clinical stage: Phase 3 clinical development.
Modality: Small-molecule fixed-dose combination (FDC)
Mechanism / Target: Combines two antihyperglycemic and antihypertensive pharmacologic components (specific agents not publicly disclosed) to address dual metabolic and cardiovascular risk factors in T2DM patients.
Route / form: Oral formulation.
Differentiation: Single-tablet regimen designed to improve treatment adherence in patients requiring both glycemic and blood-pressure control; positioned to simplify chronic management and reduce pill burden versus multi-drug regimens
Manufacturer #38615
A clinical-stage biotech firm developing next-generation nucleotide and small-molecule therapies targeting cancer and other unmet medical needs. It combines proprietary ASO and drug discovery platforms with global development and strategic partnership goals. The organization advances multiple early- to mid-stage programs through clinical and preclinical research.